ClinicalTrials.gg
Active, not recruitingNCT02823834Updated Jul 8, 2022

PMCF Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components

An observational study in Joint Disease, sponsored by MicroPort Orthopedics Inc.. Active, not recruiting at 1 site in Germany. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2022-07-08.

Sponsored by MicroPort Orthopedics Inc. (part of MicroPort Scientific Corporation) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
121
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Joint Diseases by MicroPort Scientific Corporation — 5 open to participants now, 13 under way, none of them phase 3. Joint Diseases · MicroPort Scientific Corporation.

Enrollment
8th of 20
121 · median 69
Started
2017
with 2 others
Observational
20 of 21
5 open now
Primary completion
2027-06
later than 1 of 12 live
Registered
12th of 21
by date

Among the 21 studies in Joint Diseases by MicroPort Scientific Corporation, this one is the 8th largest by enrollment of the 20 observational ones that give a count, is one of 3 that started in 2017, is one of 20 observational ones, reaches primary completion later than 1 of the 12 other live ones, and was the 12th registered.

Joint Diseases

386 studies on the registry are indexed under Joint Diseases; 64 are open to participants now.

Browse Joint Diseases studies →

Open to participants now

5 of the 21 studies in Joint Diseases by MicroPort Scientific Corporation are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 44 Joint Diseases studies recruiting now, 24 (55%) set no upper age limit and 11 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Joint Diseases by MicroPort Scientific Corporation, or all of them as a file.
02

Study summary

MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.

03

Conditions studied

  • Joint Disease

Keywords

  • osteoarthritis
  • avascular necrosis
  • ankylosis
  • protrusio acetabuli
  • painful hip dysplasia
  • rheumatoid arthritis
  • correction of functional deformity
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have been previously implanted with a PROFEMUR® Gladiator Plasma Femoral Stem and PROCOTYL® L Beaded Acetabular Component

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has undergone primary THA for any of the following:
  • Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia;
  • Inflammatory degenerative joint disease such as rheumatoid arthritis; or
  • Correction of functional deformity
  • Subject is implanted with the specified combination of components
  • Subject is willing and able to complete required study visits or assessments

Previously implanted bilateral subjects can have both THAs enrolled in the study provided:

  • the specified combination of components were implanted in both
  • all other aspects of the Inclusion/Exclusion Criteria are satisfied
  • enrollment does not exceed the subject count specified in the Clinical Trial Agreement
  • the subject agrees to a second document specific to the second THA.

Exclusion criteria

Exclusion Criteria:

  • Subjects implanted with a metal-on-metal articulation
  • Subjects implanted with non-MPO or non-Wright Medical Technology components (femoral heads, acetabular shells, acetabular liners) at the time of their primary THA in the enrolled THA
  • Subjects skeletally immature (less than 21 years of age) at time of primary THA surgery
  • Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol
  • Subjects unwilling to sign the document
  • Subjects with substance abuse issues
  • Subjects who are incarcerated or having pending incarceration
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
121 participants (actual)
Patient registry
No

Groups and cohorts

  • PROFEMUR® Gladiator Plasma Femoral Stems

    Single study group either previously implanted with the following combination of components: PROFEMUR® Gladiator Plasma Femoral Stems, PROCOTYL® L Beaded Acetabular Shells, Polyethylene or Ceramic Liners, and Metal or Ceramic Femoral Heads.

    Device: PROFEMUR® Gladiator Plasma Femoral Stems

Interventions

  • DevicePROFEMUR® Gladiator Plasma Femoral Stems

    THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components

    Also known as: Primary hip replacement device

06

What researchers measure

Primary outcomes

  1. Component Survivorship

    The primary objective of this study is to estimate survivorship analysis of all components at specified intervals out to 10 years follow-up.

    Time frame: 10 years post-operative

Secondary outcomes

  1. Patient functional outcomes (hip specific)

    To characterize total functional scores, as assessed by Oxford Hip Scores

    Time frame: 2-5 years, 5-7 years and 10 years postoperatively beginning with first available visit

  2. Patient functional outcomes (quality of life)

    To characterize total functional scores, as assessed by EQ-5D-3L scores

    Time frame: 2-5 years, 5-7 years and 10 years postoperatively beginning with first available visit

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2017 (actual). Primary completion is estimated for Jun 2027, 120 months after the start.

Of 58 observational studies under Joint Diseases, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 153. This study's planned 120 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2016
First posted
Jul 6, 2016
StartActual
Jun 16, 2017
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jul 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02823834
Responsible party
Sponsor
First posted
Jul 6, 2016
Start date
Jun 16, 2017
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 8, 2022

Study contacts

Jose Pimienta
principal investigator · Elbe Kliniken Buxtehude

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion